Evidence map›Paper›PMID 26699146›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2016

20-HETE Activates the Transcription of Angiotensin-Converting Enzyme via Nuclear Factor-κB Translocation and Promoter Binding.

Victor Garcia, Brian Shkolnik, Laura Milhau, John R Falck, Michal Laniado Schwartzman

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Association of CYP2C19 Polymorphic Markers with Cardiovascular Disease Risk Factors in Gas Industry Workers Undergoing Periodic Medical Examinations.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023
    Article
  10. Article
  11. Bioactive lipids in hypertension.Advances in pharmacology (San Diego, Calif.) · 2023
    Article
  12. Article
  13. The CYP/20-HETE/GPR75 axis in hypertension.Advances in pharmacology (San Diego, Calif.) · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Victor GarciaDepartment of Pharmacology, New York Medical College, Valhalla, New York (V.G., B.S., M.L.S.); Faculté Pharmacie Montpellier, Montpellier, France (L.M.); and Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas (J.R.F.).
Brian ShkolnikDepartment of Pharmacology, New York Medical College, Valhalla, New York (V.G., B.S., M.L.S.); Faculté Pharmacie Montpellier, Montpellier, France (L.M.); and Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas (J.R.F.).
Laura MilhauDepartment of Pharmacology, New York Medical College, Valhalla, New York (V.G., B.S., M.L.S.); Faculté Pharmacie Montpellier, Montpellier, France (L.M.); and Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas (J.R.F.).
John R FalckDepartment of Pharmacology, New York Medical College, Valhalla, New York (V.G., B.S., M.L.S.); Faculté Pharmacie Montpellier, Montpellier, France (L.M.); and Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas (J.R.F.).
Michal Laniado SchwartzmanDepartment of Pharmacology, New York Medical College, Valhalla, New York (V.G., B.S., M.L.S.); Faculté Pharmacie Montpellier, Montpellier, France (L.M.); and Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas (J.R.F.) Michal_schwartzman@nymc.edu.
The University of Texas Southwestern Medical Center · USNew York Medical College · US

Funding

Vasoregulatory Function of CYP2E1-Derived EicosanoidsP01HL034300 · NHLBI · NEW YORK MEDICAL COLLEGE · PI JIANG, HOULI · 1985 to 2015
$33.4M
Novel Eicosanoids: Synthesis and FunctionR01GM031278 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI FALCK, JOHN R. · 1985 to 2012
$4.7M
NHLBI NIH HHS HL034300NHLBI NIH HHS HL34300-26A1S1NHLBI NIH HHS P01 HL034300NIGMS NIH HHS GM31278NIGMS NIH HHS R01 GM031278
6 · The paper itself

Abstract

Increased vascular 20-hydroxyeicosatetraenoic acid (20-HETE), a cytochrome P450 arachidonic acid metabolite, promotes vascular dysfunction, injury, and hypertension that is dependent, in part, on the renin angiotensin system (RAS). We have shown that, in human microvascular endothelial cells, 20-HETE increases angiotensin-converting enzyme (ACE) mRNA, protein, and ACE activity via an epidermal growth factor receptor (EGFR)/tyrosine kinase/mitogen-activated protein kinase (MAPK)/inhibitor of κB kinase (IKK)β-mediated signaling pathway. In this work, we show that, similar to epidermal growth factor (EGF), 20-HETE (10 nM) activates EGFR by stimulating tyrosine phosphorylation; however, unlike 20-HETE, EGF does not induce ACE expression, and pretreatment with a neutralizing antibody against EGF does not prevent the 20-HETE-mediated ACE induction. Inhibition of nuclear factor κB (NF-κB) activation prevented the 4.58-fold (±0.78; P < 0.05) 20-HETE-mediated induction of ACE. The 20-HETE increased NF-κB-binding activity in nuclear extracts and the activity of both the somatic and germinal ACE promoters by 4.37-fold (±0.18; P < 0.05) and 2.53-fold (± 0.24; P < 0.05), respectively. The 20-HETE-stimulated ACE promoter activity was abrogated by the 20-HETE antagonist 20-hydroxy-6,15-eicosadienoic acid and by inhibitors of EGFR, MAPK, IKKβ, and NF-κB activation. Sequence analysis demonstrated the presence of two and one putative NF-κB binding sites on the human somatic and germinal ACE promoters, respectively. Chromatin immunoprecipitation assay indicated that 20-HETE stimulates the translocation and subsequent binding of NF-κB to each of the putative binding sites (S1, 3.43 ± 0.3-fold enrichment versus vehicle; S2, 3.72 ± 0.68-fold enrichment versus vehicle; S3, 3.20 ± 0.18-fold enrichment versus vehicle; P < 0.05). This is the first study to identify NF-κB as a transcriptional factor for ACE and to implicate a distinct EGFR/MAPK/IKK/NF-κB signaling cascade underlying 20-HETE-mediated transcriptional activation of ACE mRNA and stimulation of ACE activity.

Indexed as

Cells, CulturedEndothelial CellsHumansHydroxyeicosatetraenoic AcidsNF-kappa BPeptidyl-Dipeptidase APromoter Regions, GeneticProtein BindingTranscription, Genetic20-hydroxy-5,8,11,14-eicosatetraenoic acidHydroxyeicosatetraenoic AcidsNF-kappa BPeptidyl-Dipeptidase A

Identifiers

PMID26699146
PMCPMC4767392
OpenAlexW2313724603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.